Dipath was founded.

Received Seed round investment.

Became a permanent member of board, of Beijing Tumor Pathology Precision Diagnosis Association； The only accepted paper of digital pathology/AI in CVPR.

Series A round by IDG Capita & Legend Capital.

2018 world MedAI Innovation Challenge pathology ChampionshipAt the MedAI Challenge, Dipath won the highest award, with full score

Obtained 2 NMPA Class II Medical Device CertificatesObtained 2 certificates:
pathology scanner, and pathology assisted diagnosis software

Intelligent Photo-micrography Software D-CleverEye launchedDipath held 1st AI-aided Diagnosis Frontier Summit, released new product D-CleverEye

Series B round; partnership with AZReceived 120 million CNY investment by CICC;
Joined AstraZeneca Innovation Partner

Series B+ roundReceived Series B+ investment by SZVC and CICC

Obtained more NMPA Class II Medical Device Certificates Obtained registration certificates for IHC digital pathology image analysis software, a total of 5 Class II medical certificates

Strategic partnership with AZDipath won the "Best Ally Award" and the "Best Medical Mode Innovation Award" of AZ China，promote R&D in AI pathology, targeting the sinking market

Reported in People's DailyD-clevereye AI+Microscope diagnosis platform, supporting the work of grassroots hospitals, making headlines on the front page of People's Daily.

Strategic partnership with TakedaAt the fourth CIIE(China International Import Expo), Takeda China and Dipath on Digital Pathology reached a strategic collaboration in research and development.

Became Shortlisted productDipath's Intelligent Diagnostic Assistant product has been selected as a recommended unit for the 'Intelligent Diagnostic Assistance Products' by the Ministry of Industry and Information Technology and the National Medical Products Administration.

Strategic partnership with ZeissAt the 5th CIIE in 2022, Zeiss China and Dipath signed a strategic cooperation agreement, to achieve a win-win situation.

Series pre-C round Received Series pre-C investment, becoming the largest AI digital pathology company in the industry.

Strategic partnership with RocheRoche China announces its collaboration with Dipath, jointly launching pathology AI-assisted diagnostic algorithm products. This further accelerates China's digital and intelligent transformation in pathology diagnosis, providing strong support for the development of personalized precision medicine.